SAB Biotherapeutics to Present SAB-142 Data at EASD Conference

MIAMI, Sept. 22, 2026 /CourierPR/ -- SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 - October 2, 2026, in Milan, Italy. The presentations will highlight SAB BIO’s lead program, SAB-142, a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of Stage 3 T1D.

The company will present data at the EASD Annual Meeting, which provides an important opportunity to engage with the global diabetes community as type 1 diabetes research increasingly focuses on preserving endogenous insulin production and modifying the course of disease. The presentations will cover various aspects of SAB-142, including its mechanism of action, potential for safe redosing, and early evidence of C-peptide preservation.

SAB BIO will present its lead program, SAB-142, at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), which will be held September 28 - October 2, 2026, in Milan, Italy. The presentations will take place on Monday, September 28, 2026, from 3:00 - 5:25 PM CEST, in the INNODIA Symposium on Type 1 Diabetes Therapies session.

The presenter for this session is Christoph Bausch, PhD, MBA, Chief Operating Officer, SAB BIO. The presentation will be held at the Can we stop type 1 diabetes? session in the Station 03 location of the Milan Convention Centre.

The presenter for this session is William Quinn, PhD, Executive Director, Immunology, SAB BIO. The presentation will be held at the Can we stop type 1 diabetes? session in the Station 03 location of the Milan Convention Centre.

The presenter for this session is William Quinn, PhD, Executive Director, Immunology, SAB BIO. The presentation will be held at the Can we stop type 1 diabetes? session in the Station 03 location of the Milan Convention Centre.

Additionally, the presentations will be available as poster presentations (ePID2235, ePID2238, ePID2240) in the ePoster Area - North Wing, Central Building - in the Milan Convention Centre, Piazzale Carlo Magno 1, Milan, Italy. The presentations will be made available in the Presentations section of the Company’s website afterwards and will remain accessible following the conference.

SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of "bad acting" T-lymphocytes. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.

SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases.